Vivianna M. Van Deerlin

Vivianna M. Van Deerlin

Auto-generated profile, based on publicly available information

Vivianna M. Van Deerlin

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Nature Genetics
Verified
Journal Article
Open access
PDF file
WRWouter van Rheenen
Wouter van Rheenen
RSRick A. A. van der Spek
Rick A. A. van der Spek
MBMark K. Bakker
Mark K. Bakker
JVJoke J. F. A. van Vugt
Joke J. F. A. van Vugt
PHPaul J. Hop
Paul J. Hop
JVJan H. Veldink
Jan H. Veldink
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a lifetime risk of one in 350 people and an unmet need for disease-modifying therapies. We conducted a cross-ancestry genome-wide association study (GWAS) including 29,612 patients with ALS and 122,656 controls, which identified 15 risk loci. When combined with 8,953 individuals with whole-genome sequencing (6,538 patients, 2,415 controls) and a large cortex-derived expression quantitative trait locus (eQTL) dataset (MetaBrain), analyses revealed locus-specific genetic architectures in which we prioritized genes either through rare variants, short tandem repeats or regulatory effects. ALS-associated risk loci were shared with multiple traits within the neurodegenerative spectrum but with distinct enrichment patterns across brain regions and cell types. Of the environmental and lifestyle risk factors obtained from the literature, Mendelian randomization analyses indicated a causal role for high cholesterol levels. The combination of all ALS-associated signals reveals a role for perturbations in vesicle-mediated transport and autophagy and provides evidence for cell-autonomous disease initiation in glutamatergic neurons.

25 July 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PRParals Registry
Parals Registry
WRWouter van Rheenen
Wouter van Rheenen
SGSLALOM Group
SLALOM Group
SRSlap Registry
Slap Registry
FCFALS Sequencing Consortium
FALS Sequencing Consortium
JVJan H Veldink
Jan H Veldink

15 February 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RCRuth Chia
Ruth Chia
MSMarya S. Sabir
Marya S. Sabir
SBSara Bandres-Ciga
Sara Bandres-Ciga
SSSara Saez-Atienzar
Sara Saez-Atienzar
RRRegina H. Reynolds
Regina H. Reynolds
SSSonja Scholz
Sonja Scholz

24 January 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GGGuido Ghilardi
Guido Ghilardi
JFJoseph A. Fraietta
Joseph A. Fraietta
JGJames N. Gerson
James N. Gerson
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
JMJennifer J. D. Morrissette
Jennifer J. D. Morrissette
MRMarco Ruella
Marco Ruella

16 June 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNaomi Kouri
Naomi Kouri
OROwen A Ross
Owen A Ross
BDBeth Dombroski
Beth Dombroski
CYCurtis S. Younkin
Curtis S. Younkin
DSDaniel J. Serie
Daniel J. Serie
DDDennis W. Dickson
Dennis W. Dickson
Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10−12), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10−8), and 2p22 at SOS1 (rs963731; P=1.76 × 10−7). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10−7) and MAPT H1c (17q21; rs242557; P=7.91 × 10−6). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).

19 August 2022 in Science
Verified
Journal Article
Closed access
MDMaria E. Diaz-Ortiz
Maria E. Diaz-Ortiz
YSYunji Seo
Yunji Seo
MPMarijan Posavi
Marijan Posavi
MCMarc Carceles Cordon
Marc Carceles Cordon
ECElisia Clark
Elisia Clark
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
Many risk loci for Parkinson’s disease (PD) have been identified by genome-wide association studies (GWASs), but target genes and mechanisms remain largely unknown. We linked the GWAS-derived chromosome 7 locus (sentinel single-nucleotide polymorphism rs199347) to GPNMB through colocalization analyses of expression quantitative trait locus and PD risk signals, confirmed by allele-specific expression studies in the human brain. In cells, glycoprotein nonmetastatic melanoma protein B (GPNMB) coimmunoprecipitated and colocalized with α-synuclein (aSyn). In induced pluripotent stem cell–derived neurons, loss of GPNMB resulted in loss of ability to internalize aSyn fibrils and develop aSyn pathology. In 731 PD and 59 control biosamples, GPNMB was elevated in PD plasma, associating with disease severity. Thus, GPNMB represents a PD risk gene with potential for biomarker development and therapeutic targeting.